ATE169219T1 - Behandlung von katarakt mit 15-keto- prostaglandinderivaten - Google Patents

Behandlung von katarakt mit 15-keto- prostaglandinderivaten

Info

Publication number
ATE169219T1
ATE169219T1 AT91302925T AT91302925T ATE169219T1 AT E169219 T1 ATE169219 T1 AT E169219T1 AT 91302925 T AT91302925 T AT 91302925T AT 91302925 T AT91302925 T AT 91302925T AT E169219 T1 ATE169219 T1 AT E169219T1
Authority
AT
Austria
Prior art keywords
cataract
treatment
inderivatives
prostagland
keto
Prior art date
Application number
AT91302925T
Other languages
German (de)
English (en)
Inventor
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ATE169219T1 publication Critical patent/ATE169219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91302925T 1990-04-04 1991-04-03 Behandlung von katarakt mit 15-keto- prostaglandinderivaten ATE169219T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2931091 1991-01-29

Publications (1)

Publication Number Publication Date
ATE169219T1 true ATE169219T1 (de) 1998-08-15

Family

ID=27286510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91302925T ATE169219T1 (de) 1990-04-04 1991-04-03 Behandlung von katarakt mit 15-keto- prostaglandinderivaten

Country Status (11)

Country Link
US (2) US5212324A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0453127B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970005172B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE169219T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU644148B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2039420C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69129921T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0453127T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2119762T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3027666T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW249226B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
WO1997047595A1 (fr) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Antagoniste de l'endotheline
TR200000673T2 (tr) * 1997-09-09 2000-11-21 The Procter & Gamble Company FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
EP1012136B1 (en) * 1997-09-09 2004-07-07 Duke University Aromatic c 16?-c 20?-substituted tetrahydro prostaglandins useful as fp agonists
AU739343B2 (en) 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
MXPA02008967A (es) * 2000-03-16 2003-02-12 Sucampo Ag Tratamiento de hipertension ocular y glaucoma.
AR030275A1 (es) 2000-03-24 2003-08-20 Sucampo Pharmaceuticals Inc Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
MXPA02009915A (es) * 2000-04-06 2003-03-27 Sucampo Ag Composicion promotora de secrecion de bilis.
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1420793A1 (en) * 2001-08-23 2004-05-26 Sucampo AG Method and composition for treatment of ocular hypertension and glaucoma
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
WO2005018646A1 (ja) 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
AU2003274735B2 (en) * 2002-10-23 2008-12-04 Sucampo Ag Prostaglandin compounds for the treatment of obesity
KR101164838B1 (ko) 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
CN101146541B (zh) 2005-01-27 2012-04-11 苏坎波公司 用于治疗中枢神经系统疾病的方法和组合物
AR055038A1 (es) 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
AU2006234632B2 (en) * 2005-04-12 2011-10-27 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
MX2008009652A (es) 2006-01-24 2008-11-06 R Tech Ueno Ltd Composicion farmaceutica que comprende un compuesto biciclico y metodo para estabilizar el compuesto biciclico.
CN104971056A (zh) 2006-01-24 2015-10-14 株式会社·R-技术上野 软明胶胶囊制剂
US20090062381A1 (en) 2006-03-13 2009-03-05 Ryu Hirata Aqueous composition
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2830626A1 (en) 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia
BR112014002712A8 (pt) 2011-08-05 2017-06-20 Sucampo Ag método para tratamento da esquizofrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
US20170020890A1 (en) 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) * 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
ES2055051T3 (es) * 1988-05-23 1994-08-16 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para la fabricacion de un medicamento eficaz para aumentar la presion sanguinea.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0580268B1 (en) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Ocular hypotensive agents
TW205508B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
KR970005172B1 (ko) 1997-04-14
TW249226B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-06-11
CA2039420C (en) 1996-12-10
ES2119762T3 (es) 1998-10-16
EP0453127A2 (en) 1991-10-23
US5212324A (en) 1993-05-18
AU7404791A (en) 1991-10-10
DE69129921T2 (de) 1999-01-14
GR3027666T3 (en) 1998-11-30
US5686487A (en) 1997-11-11
KR910018027A (ko) 1991-11-30
CA2039420A1 (en) 1991-10-05
EP0453127B1 (en) 1998-08-05
EP0453127A3 (en) 1992-12-09
DE69129921D1 (de) 1998-09-10
DK0453127T3 (da) 1998-10-26
AU644148B2 (en) 1993-12-02
TW224942B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-06-11

Similar Documents

Publication Publication Date Title
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DE69213057D1 (de) Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
ATE132749T1 (de) Behandlung der hepatobilären erkrankung mit 15- ketoprostaglandin-derivaten
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ATE117208T1 (de) Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69123892D1 (de) Behandlung von Katarakt mit prostacyclinverbindungen
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee